|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,586 GBX | -0.24% |
|
-2.58% | +9.43% |
| Apr. 17 | GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix | MT |
| Apr. 17 | GSK: positive clinical results for gonorrhea | CF |
Aug 16 (Reuters) - GSK plc:
* STATEMENT: ZANTAC (RANITIDINE) U.S. LITIGATION
* NOTICE OF VOLUNTARY DISMISSAL TO BE FILED IN BAYER CASE, FIRST SCHEDULED ZANTAC TRIAL
* GSK DID NOT SETTLE BAYER’S CLAIM AND HAS NOT PAID ANYTHING IN EXCHANGE FOR THE VOLUNTARY DISMISSAL
* GSK WILL CONTINUE TO VIGOROUSLY DEFEND ITSELF AGAINST ALL CLAIMS ALLEGING CANCER RISK ASSOCIATED WITH THE USE OF RANITIDINE Source text for Eikon: Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| +9.43% | 80.88B | |
| +28.79% | 676B | |
| +25.21% | 554B | |
| -7.64% | 349B | |
| +15.00% | 318B | |
| +5.99% | 291B | |
| +3.26% | 210B | |
| -0.31% | 204B | |
| -9.73% | 194B | |
| -11.71% | 144B |
GSK PLC 
